Rhythm Pharmaceuticals Inc

9 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals shares advanced after BofA set a new price target of $150, supported by positive feedback on its MC4R franchise for adult hypothalamic obesity.

8 de out. de 2026, 20:01 UTC

RBC Capital raises Rhythm Pharmaceuticals price target to $159.00 from $155.00 while maintaining an Outperform rating, citing strong market performance over five years.

7 de out. de 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, remaining well below their 20-day moving average and significantly lower compared to Tuesday's close.

6 de out. de 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving further below its 20-day moving average since Tuesday's close.

5 de out. de 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of six consecutive daily declines and remaining below its 20-day moving average.

2 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions in the red and remaining below the 20-day moving average.

1 de out. de 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is advancing in after-market trading, gaining ground since Thursday's close while currently trading below its 20-day moving average.

29 de set. de 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, declining notably from Monday's close and trading well below its 20-day moving average amid ongoing pressure.

24 de set. de 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell modestly, currently near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.

23 de set. de 2026, 22:25 UTC

Rhythm Pharmaceuticals Inc is rising in after-market trading, recovering from an initial dip and advancing since Wednesday's close, though still below its 20-day moving average.

22 de set. de 2026, 20:07 UTC

Rhythm Pharmaceuticals' IMCIVREE® received Health Canada approval for weight management in patients with acquired hypothalamic obesity, boosting shares higher during the session.

21 de set. de 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc is higher today, continuing an upward trend since Friday, despite mid-morning volatility and remaining below its 20-day moving average.

18 de set. de 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, settling near the lower end of their one-month range and significantly below the 20-day moving average.

17 de set. de 2026, 20:07 UTC

Rhythm Pharmaceuticals advances during Thursday's session, boosted by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

16 de set. de 2026, 20:10 UTC

Rhythm Pharmaceuticals Inc is experiencing an upward movement during Wednesday's trading session, recovering from an early low with a peak return of 4.17%.

15 de set. de 2026, 20:01 UTC

Rhythm Pharmaceuticals shares are lower amid concerns from CEO insider selling and a drop in the NY Empire State Manufacturing Index for September.

14 de set. de 2026, 20:08 UTC

Rhythm Pharmaceuticals Inc. shares are lower today, continuing a decline since Friday's close, despite an earlier rebound from session lows.

11 de set. de 2026, 19:52 UTC

Rhythm Pharmaceuticals shares are higher during Friday's session, pulling back from earlier gains. No specific news was identified to explain the movement.

8 de set. de 2026, 20:08 UTC

RYTM trades lower as the biotech sector faces pressure.

2 de set. de 2026, 20:08 UTC

Rhythm Pharmaceuticals is higher today, supported by gains in the Biotechnology sector and CFO share transactions that reflect confidence in future performance.

1 de set. de 2026, 19:26 UTC

Rhythm Pharmaceuticals reported a net loss of -$33.26 million on revenue of $17.28 million. Shares are lower, continuing a trend of three consecutive sessions finishing down.

31 de ago. de 2026, 23:46 UTC

Rhythm Pharmaceuticals Inc shares rose in after-market trading, reflecting a gradual increase from earlier lows, though still below the 20-day moving average.

28 de ago. de 2026, 20:02 UTC

Rhythm Pharmaceuticals Inc shares are lower as Deutsche Bank initiates coverage with a Hold rating and a price target of $120.

26 de ago. de 2026, 20:08 UTC

Rhythm Pharmaceuticals is trading lower, influenced by declines in the Biotechnology sector and a broader market downturn since Tuesday's close.

25 de ago. de 2026, 21:02 UTC

Rhythm Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline, contrasting recent upward trends.

21 de ago. de 2026, 19:36 UTC

Rhythm Pharmaceuticals Inc shares are higher during Friday's session, reflecting positive market response. The stock reached a session high earlier before pulling back.

20 de ago. de 2026, 20:02 UTC

Rhythm Pharmaceuticals is lower today, influenced by a significant decline in the Biotechnology sector and high trading volume. The stock has dropped sharply since Wednesday.

13 de ago. de 2026, 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

12 de ago. de 2026, 19:46 UTC

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11 de ago. de 2026, 19:36 UTC

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.